Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHEREThe VENTANA FOLR1 RxDx Assay facilitates targeted treatment for ovarian cancer patients with ELAHERE, offering a crucial diagnostic tool in Europe.